Dr. Assi is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine (BUSM) and a medical oncologist in the section of Hematology/Oncology at Boston Medical Center (BMC). He graduated from medical school at the American University of Beirut in Lebanon and completed his residency in Internal Medicine at Albany Medical Center in Albany, NY. He further completed his training in Hematology/Oncology at University of Oklahoma Health Sciences Center, while also receiving a Master’s degree in Clinical and Translational Sciences. His work is focuses on gastrointestinal malignancies, with special focus on neuroendocrine tumors (NETs). His aim is to establish himself as an independent clinical investigator, with a focus on delivering novel therapeutics in NETs. His current research focuses on studying prognostic biomarkers in pancreatic NETs.
- Amer Univ of Beirut, MD
- University of Oklahoma, MS
- Amer Univ of Beirut, BS
- Published on 8/2/2022
Hackeng WM, Assi HA, Westerbeke FHM, Brosens LAA, Heaphy CM. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. Surg Pathol Clin. 2022 Sep; 15(3):541-554. PMID: 36049835.
- Published on 7/1/2021
Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas. 2021 07 01; 50(6):890-894. PMID: 34398071.
- Published on 10/1/2020
Assi HA, Shikdar S, Alhyari L, Aljumaily R. Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer. Pancreas. 2020 10; 49(9):e95-e96. PMID: 33003100.
- Published on 6/25/2020
Assi HA, Asch AS, Machiorlatti M, Vesely SK, Ibrahimi S. Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy. Future Sci OA. 2020 Jun 25; 6(7):FSO581. PMID: 32802390.
- Published on 2/1/2020
Assi HA, Mukherjee S, Machiorlatti M, Vesely S, Pareek V, Hatoum H. Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database. Anticancer Res. 2020 Feb; 40(2):847-855. PMID: 32014928.
- Published on 1/23/2020
Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P. Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. J Urol. 2020 07; 204(1):63-70. PMID: 31971495.
- Published on 1/16/2020
Assi HA, Padda SK. Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung. Cancer Treat Res Commun. 2020 Jan 16; 23:100167. PMID: 32007735.
- Published on 12/12/2019
Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020 03 15; 126(6):1208-1216. PMID: 31829450.
- Published on 10/2/2019
Assi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, Hatoum H. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. Oncologist. 2020 02; 25(2):e276-e283. PMID: 32043766.
- Published on 10/1/2015
Assi HA, Patel R, Mehdi S. Neuroendocrine carcinoma of the larynx with metastasis to the eyelid. J Community Support Oncol. 2015 Oct; 13(10):378-80. PMID: 26862914.
View 8 more publications: View full profile at BUMC